Sanofi-Aventis Pares Pipeline, Ditches Antidepressant Amibegron

In light of clinical setbacks and a broader overhaul, Sanofi-Aventis has ended some once-promising advanced development programs, while the fates of others hang in the balance, pending study results and strategic reviews